Ascentage Pharma Group International(AAPG)Earnings, Financials & Key Ratios
AAPG•NASDAQ
$19.37
Price updated Jul 6, 2026
AboutAscentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.Show more
- Revenue$558M-43.1%
- EBITDA-$1.1B-295.9%
- Net Income-$1.21B-198.2%
- EPS (Diluted)-13.56-153.0%
- Gross Margin76.41%-21.3%
- EBITDA Margin-196.08%-595.3%
- Operating Margin-211.14%-460.0%
- Net Margin-216.47%-423.6%
- ROE-150.25%+36.1%
AAPG Price & Volume
Ascentage Pharma Group International (AAPG) stock price & volume — 10-year historical chart
Loading chart...
Milestone Volatility Masks High R&D Burn Rate
Investment Thesis • Updated 2025Q4
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Clinical milestone dependency
Key Thesis Takeaways
- Ascentage Pharma operates a high-risk, milestone-dependent business model that currently struggles to achieve consistent profitability despite maintaining gross margins above 75%.
- While the company's $2.5B cash position provides a necessary buffer for its aggressive $587.5M quarterly R&D expenditure, the reliance on non-recurring licensing revenue creates significant earnings instability.
- Investors should monitor the company's ability to transition from clinical-stage development to sustainable commercial product sales to justify its current $2.0B debt load.
Verdict Logic
while the $2.5B cash reserve offers a current ratio of 1.79, the company's inability to generate consistent positive free cash flow or sustained net income, as seen in the -$640.0M net loss for 2025Q4, warrants a cautious wait-and-see approach.
AAPG Growth Metrics
Ascentage Pharma Group International (AAPG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years113.98%
3 Years38.61%
TTM258.7%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.53%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM82.16%
Return on Capital
10 Years-41.65%
5 Years-43.46%
3 Years-45.55%
Last Year-62.51%
AAPG Recent Earnings
Ascentage Pharma Group International (AAPG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (50%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
Mar 24, 2026Metric
Actual
Est
EPS
$0.65+21.7%
$0.83
Rev
$49M+11.5%
$44M
Q3 2025
Aug 20, 2025Metric
Actual
Est
EPS
$0.96
—
Rev
$33M
—
Q2 2025
Mar 27, 2025Metric
Actual
Est
EPS
$1.00-6134.6%
$0.02
Rev
$21M
—
Q4 2024
Dec 31, 2024Metric
Actual
Est
EPS
$0.25
—
Rev
$21M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $0.65vs $0.83+21.7% | $49Mvs $44M+11.5% |
| Q3 2025 | Aug 20, 2025 | $0.96 | $33M |
| Q2 2025 | Mar 27, 2025 | $1.00vs $0.02-6134.6% | $21M |
| Q4 2024 | Dec 31, 2024 | $0.25 | $21M |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Ascentage Pharma Group International (AAPG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $19.37 | $1.79B | -9.70 | -43.05% | -216.47% | -150.25% | — | |
| $254.76 | $450.11B | 107.49 | 8.57% | 5.79% | 67.46% | — | |
| $4.58 | $5.78M | -0.09 | -81.82% | -2530.85% | — | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $8.45 | $545.2M | -6.60 | -0.3% | -247.54% | -44.39% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — |
Compare AAPG vs Peers
Ascentage Pharma Group International (AAPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when AAPG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AAPG Frequently Asked Questions
Ascentage Pharma Group International (AAPG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Ascentage Pharma Group International's revenue?
Ascentage Pharma Group International (AAPG) reported $1.55B in revenue for fiscal year 2025. This represents a 20097% increase from $7.7M in 2016.
How fast is Ascentage Pharma Group International growing?
Ascentage Pharma Group International (AAPG) saw revenue decline by 43.1% over the past year.
Is AAPG profitable?
Ascentage Pharma Group International (AAPG) reported a net loss of $1.64B for fiscal year 2025.
Dividend & Returns
What is AAPG's return on equity?
Ascentage Pharma Group International (AAPG) has a return on equity (ROE) of -150.2%. Negative ROE indicates the company is unprofitable.
What is Ascentage Pharma Group International's free cash flow?
Ascentage Pharma Group International (AAPG) had negative free cash flow of $1.38B in fiscal year 2025, likely due to heavy capital investments.